(Q41552408)

3 October 2017

Activity of anthracyclines in refractory ovarian cancer: recent experience and review (English)

1 reference

3 October 2017

1 reference

2

1 reference

3 October 2017

Garcia A

1

1 reference

PubMed ID

9246155

3 October 2017

language of work or name

1 reference

1 January 1997

1 reference

3 October 2017

1 reference

3 October 2017

15

1 reference

3 October 2017

4

1 reference

3 October 2017

329-334

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

3 October 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Adriamycin and bleomycin, alone and in combination, in gynecologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Adriamycin in ovarian cancer patients resistant to cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Impact of doxorubicin on survival in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709039736

10.3109/07357909709039736

21 January 2018

Identifiers

DOI

1 reference

3 October 2017

1 reference

PubMed ID

9246155